

StemRIM Announces Patent Registration in Australia for Peptides Related to the HMGB1 Fragment Peptide, Redasemtide

Osaka, Japan, December 5, 2024 – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; “StemRIM” or “Company”) announces that a substance patent for the peptides related to “Regeneration-Inducing Medicine™” development candidate, Redasemtide, will be registered in Australia as detailed below.

Title of Invention : Peptide for Inducing Regeneration of Tissue and Use Thereof
Region : Australia
Application No. : 2022201894
Registration No. : To be determined
Applicant : StemRIM Inc.

This patent comprehensively covers the substance patent for the related peptides, in addition to the substance patent for Redasemtide already obtained in Australia. With this patent, our company will hold rights not only to Redasemtide but also to similar substances that have or may have regenerative induction effects. This will prevent the development of generics and counterfeit products, thereby ensuring our development advantage in the Australia market for “Regeneration-Inducing Medicine™”.

The pharmaceutical market in Australia reached approximately 10.5 billion dollars in 2022. Although it has shown a slight decline in recent years, stable growth is expected in the future due to an aging population and an increase in chronic diseases. In this mature market, “Regeneration-Inducing Medicine™”, which is industrially producible and provides effects equivalent to traditional cell and regenerative therapies, is considered highly advantageous compared to existing drugs and treatment methods in terms of cost efficiency and safety.

The impact on the financial performance for the fiscal year ending July 31, 2025, is insignificant. We will promptly disclose any additional information that needs to be disclosed.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called “Regeneration-Inducing Medicine™”. The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. “Regeneration-Inducing Medicine™” is aimed at

maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.

Management & Administrator Dept.

E-Mail: stemrim-ir@stemrim.com

Twitter: [@StemRIM_Inc](https://twitter.com/StemRIM_Inc)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)